Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: A longitudinal brain imaging study

Neuropsychopharmacology

Volumn 35, Issue 8, 2010, Pages 1743-1750

  Lyoo, In Kyoon ^a   Dager, Stephen R ^b,c   Kim, Jieun E ^a   Yoon, Sujung J ^d   Friedman, Seth D ^c   Dunner, David L ^e   Renshaw, Perry F ^f,g,h  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Washington   (United States)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Center for Anxiety and Depression   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Bipolar disorder; Clinical response; Gray matter; Lithium; Magnetic resonance imaging; Valproic acid

Indexed keywords

LITHIUM; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MALE; NERVE CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TREATMENT RESPONSE; WHITE MATTER;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LITHIUM CHLORIDE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; TIME FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 77953568012     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.41     Document Type: Article

References (44)

1. Ananth H, Popescu I, Critchley HD, Good CD, Frackowiak RS, Dolan RJ (2002). Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry 159: 1497-1505.
2. Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM (2003). Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol 2: 79-88.
3. Ashburner J, Friston KJ (2001). Why voxel-based morphometry should be used. Neuroimage 14: 1238-1243.
4. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M et al (2007). Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62: 7-16.
5. Bell EC, Willson MC, Wilman AH, Dave S, Silverstone PH (2005). Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. Hum Psychopharmacol 20: 415-424.
6. Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH (2002). The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 15: 259-267.
7. Chen G, Huang LD, Jiang YM, Manji HK (1999a). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
8. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al (1999b). The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72: 879-882.
9. Chuang DM, Manji HK (2007). In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 62: 4-6.
10. Coyle JT, Duman RS (2003). Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 157-160.
11. Coyle JT, Manji HK (2002). Getting balance: drugs for bipolar disorder share target. Nat Med 8: 557-558.
12. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK et al (2004). Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61: 450-458.
13. Drevets WC, Price JL, Simpson Jr JR, Todd RD, Reich T, Vannier M et al (1997). Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386: 824-827.
14. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L et al (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23: 7311-7316.
15. Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL et al (2004). Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry 56: 340-348.
16. Gilbert AR, Moore GJ, Keshavan MS, Paulson LA, Narula V, Mac Master FP et al (2000). Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch Gen Psychiatry 57: 449-456.
17. Gueorguieva R, Krystal JH (2004). Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61: 310-317.
18. Gurvich N, Klein PS (2002). Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 96: 45-66.
19. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
20. Hennen J (2003). Statistical methods for longitudinal research on bipolar disorders. Bipolar Disord 5: 156-168.
21. Hennion JP, el-Masri MA, Huff MO, el-Mailakh RS (2002). Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord 4: 201-206.
22. Jorda EG, Verdaguer E, Morano A, Jimenez A, Canudas AM, Camins A et al (2004). Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons. Bipolar Disord 6: 144-149.
23. Keller A, Castellanos FX, Vaituzis AC, Jeffries NO, Giedd JN, Rapoport JL (2003). Progressive loss of cerebellar volume in childhood-onset schizophrenia. Am J Psychiatry 160: 128-133.
24. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM (2008). Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 65: 1017-1032.
25. Kessing LV, Nilsson FM (2003). Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 73: 261-269.
26. Kessing LV, Sondergard L, Forman JL, Andersen PK (2008). Lithium treatment and risk of dementia. Arch Gen Psychiatry 65: 1331-1335.
27. Lagace DC, Eisch AJ (2005). Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant? Psychiatr Clin North Am 28: 399-414.
28. Li X, Ketter TA, Frye MA (2002). Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord 69: 1-14.
29. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ et al (2006). Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 8: 65-74.
30. Manji HK, Moore GJ, Chen G (1999). Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46: 929-940.
31. Martinowich K, Manji H, Lu B (2007). New insights into BDNF function in depression and anxiety. Nat Neurosci 10: 1089-1093.
32. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000). Lithium-induced increase in human brain grey matter. Lancet 356: 1241-1242.
33. Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW et al (2009). A longitudinal study of the effects of lithium treatment on prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 70: 699-705.
34. Phatak P, Shaldivin A, King LS, Shapiro P, Regenold WT (2006). Lithium and inositol: effects on brain water homeostasis in the rat. Psychopharmacology (Berl) 186: 41-47.
35. Phillips ML, Travis MJ, Fagiolini A, Kupfer DJ (2008). Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 165: 313-320.
36. Rajkowska G (2000). Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48: 766-777.
37. Sassi RB, Nicoletti M, Brambilla P, Mallinger AG, Frank E, Kupfer DJ et al (2002). Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 329: 243-245.
38. Scherk H, Falkai P (2006). Effects of antipsychotics on brain structure. Curr Opin Psychiatry 19: 145-150.
39. Schou M (1997). Forty years of lithium treatment. Arch Gen Psychiatry 54: 9-13.
40. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC (2003). Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 18: 73-79.
41. Wada A, Yokoo H, Yanagita T, Kobayashi H (2005). Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 99: 307-321.
42. Williams RS, Cheng L, Mudge AW, Harwood AJ (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
43. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435.
44. Yücel K, McKinnon MC, Taylor VH, MacDonald K, Alda M, Young LT et al (2007). Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl) 195: 357-367.